Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Barclays Maintains Equal-Weight on AbbVie, Lowers Price Target to $155

Barclays analyst Carter Gould maintains AbbVie (NYSE:ABBV) with a Equal-Weight and lowers the price target from $160 to $155.
byBenzinga Newsdesk
October 31, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Barclays analyst Carter Gould maintains AbbVie (NYSE:ABBV) with a Equal-Weight and lowers the price target from $160 to $155.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts